• 대한화장품학회지
• /
• 제47권1호
• /
• pp.65-73
• /
• 2021

피부 염증은 흉터, 노화 뿐만 아니라 아토피와 같은 질환으로 발전할 수 있어 이를 조절하는 것이 매우 중요하다. 본 연구에서는 최근 인체에서 염증을 조절하는 것으로 알려진 specialized pro-resolving mediators (SPMs)의 in vitro 합성과 화장품 적용 가능성을 확인하였다. 대두의 lipoxygenase를 이용하여 mono 또는 di-hydroxy docosahexaenoic acid가 혼합된 시료 S-SPMs를 제작하였고 효능 평가에 이용하였다. 먼저, UVB로 염증을 유도한 세포에서 TNF-α와 IL-6의 발현이 S-SPMs에 의해 감소하고, 미세먼지에 의해 유도된 nitric oxide (NO)의 생성 역시 감소하는 것을 확인하여 S-SPMs의 항염 효능을 확인하였다. 또한, S-SPMs을 처리한 조건에서 malondialdehyde (MDA) 생성이 감소하여 지질 과산화 억제능이 있음을 확인하였고 S-SPMs에 의한 matrix metalloproteinase-1 (MMP-1)의 발현 감소, procollagen type I의 함량 증가를 통해 collagen 분해를 억제하고 반대로 합성은 촉진함을 확인하였다. 끝으로 filaggrin과 loricrin의 발현이 S-SPMs에 의해 증가한 것을 확인하여 피부 장벽 강화 효능을 확인하였다. 위 결과를 토대로 S-SPMs은 피부의 염증 억제와 함께 손상회복, 주름개선 및 장벽 강화를 위한 소재로 활용 가능함을 확인하였다.

• Biomolecules & Therapeutics
• /
• 제29권5호
• /
• pp.455-464
• /
• 2021

Uncontrolled inflammation is considered the pathophysiological basis of many prevalent metabolic disorders, such as nonalcoholic fatty liver disease, diabetes, obesity, and neurodegenerative diseases. The inflammatory response is a self-limiting process that produces a superfamily of chemical mediators, called specialized proresolving mediators (SPMs). SPMs include the ω-3-derived family of molecules, such as resolvins, protectins, and maresins, as well as arachidonic acid-derived (ω-6) lipoxins that stimulate and promote resolution of inflammation, clearance of microbes, and alleviation of pain and promote tissue regeneration via novel mechanisms. SPMs function by binding and activating G protein-coupled receptors, such as FPR2/ALX, GPR32, and ERV1, and nuclear orphan receptors, such as RORα. Recently, several studies reported that SPMs have the potential to attenuate lipid metabolism disorders. However, the understanding of pharmacological aspects of SPMs, including tissue-specific biosynthesis, and specific SPM receptors and signaling pathways, is currently limited. Here, we summarize recent advances in the role of SPMs in resolution of inflammatory diseases with metabolic disorders, such as nonalcoholic fatty liver disease and obesity, obtained from preclinical animal studies. In addition, the known SPM receptors and their intracellular signaling are reviewed as targets of resolution of inflammation, and the currently available information on the therapeutic effects of major SPMs for metabolic disorders is summarized.

• The Korean Journal of Physiology and Pharmacology
• /
• 제24권2호
• /
• pp.165-171
• /
• 2020

Ischemic and traumatic brain injuries are the major acute central nervous system disorders that need to be adequately diagnosed and treated. To find biomarkers for these acute brain injuries, plasma levels of some specialized pro-resolving mediators (SPMs, i.e., lipoxin A4 [LXA4], resolvin [Rv] E1, RvE2, RvD1 and RvD2), CD59 and interleukin (IL)-6 were measured at 0, 6, 24, 72, and 168 h after global cerebral ischemic (GCI) and traumatic brain injuries (TBI) in rats. Plasma LXA4 levels tended to increase at 24 and 72 h after GCI. Plasma RvE1, RvE2, RvD1, and RvD2 levels showed a biphasic response to GCI; a significant decrease at 6 h with a return to the levels of the sham group at 24 h, and again a decrease at 72 h. Plasma CD59 levels increased at 6 and 24 h post-GCI, and returned to basal levels at 72 h post-GCI. For TBI, plasma LXA4 levels tended to decrease, while RvE1, RvE2, RvD1, and RvD2 showed barely significant changes. Plasma IL-6 levels were significantly increased after GCI and TBI, but with different time courses. These results show that plasma LXA4, RvE1, RvE2, RvD1, RvD2, and CD59 levels display differential responses to GCI and TBI, and need to be evaluated for their usefulness as biomarkers.